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in routine care. METHODS AND RESULTS ETNA-AF-Europe is a prospective, multi-centre, post-
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ETNA-AF-Europe is a prospective, multicentre, post-authorization, observational study enrolling patients treated with
edoxaban in 10 European countries, the design of which was agreed with the European Medicines Agency as part of
edoxaban’s post-approval safety plan. Altogether 13 092 patients in 852 sites completed the 1-year follow-up [mean age:
73.6± 9.5 years; 57% male, mean follow-up: 352± 49days (median: 366days)]. Most patients had associated comorbidities
(mean CHA2DS2-VASc score: 3.1± 1.4). Stroke or systemic embolism was reported in 103 patients (annualized event
rate: 0.82%/year), and major bleeding events were reported in 132 patients (1.05%/year). Rates of intracranial haemor-
rhage were low [30 patients (0.24%/year)]. Death occurred in 442 patients (3.50%/year); cardiovascular (CV) death
occurred in 206 patients (1.63%/year). The approved dosing of edoxaban was chosen in 83%. All-cause and CV mortality
were higher in patients receiving edoxaban 30mg vs. 60mg, in line with the higher age and more frequent comorbidities
of the 30mg group. Major bleeding was also numerically more common in patients receiving edoxaban 30mg vs. 60mg.
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Conclusion The rates of stroke, systemic embolism, and major bleeding are low in this large unselected cohort of high-risk AF
patients routinely treated with edoxaban.
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Introduction
Atrial fibrillation (AF) is a growing epidemic, currently affecting 1.5–
3% of European populations.1,2 Oral anticoagulation is key for reduc-
ing the risk of stroke in patients with AF. Non-vitamin K antagonist
oral anticoagulants (NOACs) are at least as effective as vitamin K
antagonists (VKAs) in controlled clinical trials, with a lower risk of
intracranial haemorrhage (ICH) and overall a lower mortality than
VKAs.3 Non-vitamin K oral anticoagulant use in clinical practice is in-
creasingly becoming the standard of care. Several registries4–6 and
retrospective analyses7,8 have assessed outcomes of three (apixaban,
dabigatran, and rivaroxaban) of the four available NOACs, but rou-
tine clinical data on edoxaban, the fourth NOAC that entered the
clinical arena, are scarce. Regulators such as the European Medicines
Agency have regularly requested for data on the safety of recently
approved therapies in routine clinical care as part of the post-
approval safety plan of these recently approved medications.
Edoxaban, a once daily, direct factor Xa inhibitor, is approved for
stroke prevention in adult patients with AF, as well as for the treat-
ment and secondary prevention of venous thromboembolism. The
recommended dose for all indications is 60mg edoxaban once daily
with a reduced dose of 30mg once daily in patients with one or more
of the following clinical factors: moderate or severe renal impairment
[creatinine clearance (CrCl) 15–50mL/min], low body weight
<_60 kg, or concomitant use of certain P-glycoprotein (P-gp) inhibi-
tors.9 Edoxaban was shown to be effective and safe in a wide range of
patient populations included in the randomized ENGAGE AF-TIMI
48 trial.10–12 However, data on its effectiveness and safety in routine
clinical care is still limited in the European population.
Here, we present the 1-year outcomes of stroke, bleeding, and
mortality from the Edoxaban Treatment in Routine Clinical Practice
for Patients With Non Valvular Atrial Fibrillation (ETNA-AF-Europe)
study conducted in unselected European patients with AF.
Methods
ETNA-AF-Europe (Clinicaltrials.gov: NCT02944019) is a multinational,
multicentre, post-authorization, observational study conducted in 852
sites in 10 European countries (Austria, Belgium, Germany, Ireland, Italy,
The Netherlands, Portugal, Spain, Switzerland, and UK). ETNA-AF-
Europe is part of the global ETNA initiative, which is composed of separ-
ate, non-interventional prospective ETNA-AF registries in Europe, East
Asia, and Japan. The design of the ETNA-AF-Europe was agreed in close
collaboration with the European Medicines Agency (EMA) and has been
previously published.13,14 The study was approved by the institutional re-
view boards and independent Ethics Committees for all participating
centres in compliance with the Declaration of Helsinki and Guidelines for
Good Pharmacoepidemiological Practice (GPP). All participants provided
written informed consent.
Unselected routine patients with AF treated with edoxaban, providing
consent, were prospectively enrolled. Explicit exclusion criteria were not
defined. The primary objective of ETNA-AF-Europe is to assess the rou-
tine clinical care safety of edoxaban by evaluating bleeding events, includ-
ing ICH; drug-related adverse events; and cardiovascular (CV) and all-
cause mortality in routine care patients with AF treated with edoxaban
up to 4 years, with regard to onset (relative to treatment with edoxaban),
duration, severity and outcomes of the events. Details of the inclusion cri-
teria and secondary objectives can be found in the ETNA-AF-Europe de-
sign paper.13 Here, we present 1-year follow-up outcomes of the first
13 092 patients as captured on 31October 2019.
Besides description of patients’ characteristics and outcomes, event
rates are compared descriptively with event rates reported amongst
non-Asian patients included in the Effective Anticoagulation with Factor
Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial
Infarction 48 (ENGAGE AF-TIMI 48) study. In ETNA-AF-Europe, all
patients were included, including a minority of Asians living in Europe.
From ENGAGE AF-TIMI 48, ‘non-Asian’ self-designated patients were
used to contextualize against ETNA-AF-Europe data, in view of a sub-
analysis that has confirmed a preferential efficacy with edoxaban in Asian
vs. non-Asian patients.15 Therefore, the side-by-side presentation of
ETNA-AF-Europe and ENGAGE AF-TIMI 48 in this paper is intended to
be a conservative exercise.
Statistical analysis
Baseline characteristics are summarized descriptively as frequencies (n
and percentage), mean value ± standard deviation (SD) rounded to inte-
ger, or median [interquartile range (IQR)]. Based on the reported events,
annualized event rates (% per year) are presented for the main safety and
efficacy outcomes. Other outcomes were specified in the design paper.13
The events presented here for ETNA-AF-Europe are as reported by the
site investigator.
Kaplan–Meier curves were used to present the cumulative event rates
of stroke/systemic embolism (SE), major bleeding, and all-cause mortality.
A stepwise logistic regression model was used to identify the factors
related to all-cause mortality and major bleeding.
Results
Baseline characteristics
Baseline characteristics of ETNA-AF-Europe patients completing
follow-up (N=13 092) were broadly similar to the non-Asian ethni-
city cohort of ENGAGE AF-TIMI 48. Mean age was slightly higher in
ETNA-AF-Europe with more than half of all patients aged >_75 years,
whereas the CHA2DS2-VASc score was slightly lower and the HAS-
BLED bleeding risk score was slightly higher in patients included in
ETNA-AF-Europe compared with the non-Asian ENGAGE AF-TIMI
48 population (Table 1), reflecting the broader indications for edoxa-
ban compared with the inclusion criteria of ENGAGE AF-TIMI 48.
In ETNA-AF-Europe, the mean body weight was 81± 17 kg and
body mass index (BMI) was 28± 5 kg/m2. The mean (± SD) and me-
dian follow-up duration was 352± 49 and 366 days. AF at first




























































































Table 1 Baseline demographics and clinical characteristics of patients included in ETNA-AF-Europe and ENGAGE
AF-TIMI 48








adj. to 30 mg
Patients, n (%) 13092 (100%) 9991 (76.3%) 3101 (23.7%) 6056 (100%) 4747 (78.4%) 1309 (21.6%)
Male, n (%) 7430 (56.8%) 6061 (60.7%) 1369 (44.1%) 3696 (61.0%) 3160 (66.6%) 536 (40.9%)
Age (years), mean ± SD 73.6 ± 9.46 71.8 ± 9.14 79.5 ± 7.92 70.9 ± 9.41 69.2 ± 9.17 77.1 ± 7.47
By age sub-groups, n (%)
<65 years 1994 (15.2%) 1861 (18.6%) 133 (4.3%) 1544 (29.5%) 1445 (30.4%) 99 (7.6%)
65–74 years 4456 (34.0%) 3896 (39.0%) 560 (18.1%) 2007 (33.1%) 1731 (36.5%) 276 (21.1%)
>_75 years 6640 (50.7%) 4233 (42.4%) 2407 (77.6%) 2505 (41.4%) 1571 (33.1%) 934 (71.4%)
<85 years 11718 (89.5%) 9467 (94.8%) 2251 (72.6%) 5772 (95.3%) 4649 (97.9%) 1123 (85.8%)
>_85 years 1372 (10.5%) 523 (5.2%) 849 (27.4%) 284 (4.7%) 98 (2.1%) 186 (14.2%)
Body weight (kg), mean ± SD 81.0 ± 17.29 83.5 ± 16.75 72.9 ± 16.51 86.9 ± 19.94 91.2 ± 18.88 71.5 ± 15.61
BMI (kg/m2), mean ± SD 28.1 ± 5.11 28.6 ± 5.05 26.5 ± 5.00 30.3 ± 5.99 31.3 ± 5.87 26.6 ± 4.89
CrCl (recalc.) (mL/min), mean ± SD 74.3 ± 30.42 82.1 ± 29.19 50.3 ± 19.61 78.7 ± 32.05 86.6 ± 30.19 50.0 ± 20.05
Patients fulfilling >_1 dose adjustment
criteria, n (%)
3106 (23.7%) 1119 (11.2%) 1987 (64.1%) NA NA NA
CHADS2, mean ± SD 1.7 ± 1.07 1.6 ± 1.05 2.1 ± 1.03 2.9 ± 0.97 2.8 ± 0.94 3.1 ± 1.06
CHA2DS2-VASc, mean ± SD 3.1 ± 1.40 2.9 ± 1.37 3.8 ± 1.27 4.3 ± 1.41 4.2 ± 1.36 5.0 ± 1.39
By CHA2DS2-VASc, n (%)
CHA2DS2-VASc score (<4), n (%) 8184 (62.5%) 6878 (68.8%) 1306 (42.1%) 1767 (29.2%) 1601 (33.7%) 166 (12.7%)
CHA2DS2-VASc score (>_4), n (%) 4908 (37.5%) 3113 (31.2%) 1795 (57.9%) 4289 (70.8%) 3146 (66.3%) 1143 (87.3%)
mod. HAS-BLED, mean ± SD 2.5 ± 1.10 2.4 ± 1.08 2.9 ± 1.06 1.5 ± 0.94 1.4 ± 0.94 1.8 ± 0.89
Frailtya, n (%)
Yes 1392 (10.6%) 612 (6.1%) 780 (25.2%) NA NA NA
No 10820 (82.7%) 8719 (87.3%) 2101 (67.8%) NA NA NA
Not known 878 (6.7%) 658 (6.6%) 220 (7.1%) NA NA NA
Previous history of CV disease, n (%)
Hypertension 10088 (77.1%) 7594 (76.0%) 2494 (80.4%) 5763 (95.2%) 4546 (95.8%) 1217 (93.0%)
Congestive heart failure 777 (5.9%) 478 (4.8%) 299 (9.6%) 3598 (59.4%) 2847 (60.0%) 751 (57.4%)
Myocardial infarction 560 (4.3%) 371 (3.7%) 189 (6.1%) 731 (12.1%) 568 (12.0%) 163 (12.5%)
Peripheral artery disease 437 (3.3%) 278 (2.8%) 159 (5.1%) 253 (4.2%) 177 (3.7%) 76 (5.8%)
Previous history of diabetes mellitus, n (%) 2879 (22.0%) 2057 (20.6%) 822 (26.5%) 2221 (36.7%) 1833 (38.6%) 388 (29.6%)
Previous history of COPD, n (%) 1206 (9.2%) 824 (8.2%) 382 (12.3%) 553 (9.1%) 404 (8.5%) 149 (11.4%)
Previous history of stroke and ICH, n (%)
Ischaemic strokeb 778 (5.9%) 564 (5.6%) 214 (6.9%) 998 (16.5%) 772 (16.3%) 226 (17.3%)
Intracranial haemorrhage 62 (0.5%) 45 (0.5%) 17 (0.5%) 7 (0.1%) 4 (0.1%) 3 (0.2%)
Previous history of bleeding, n (%)
Major 129 (1.0%) 80 (0.8%) 49 (1.6%) NA NA NA
Major or CRNM 270 (2.1%) 160 (1.6%) 110 (3.5%) NA NA NA
Current AF type, n (%)
Paroxysmal 7039 (53.9%) 5473 (54.9%) 1566 (50.6%) 1542 (25.5%) 1194 (25.2%) 348 (26.6%)
Persistent 3159 (24.2%) 2496 (25.0%) 663 (21.4%) 1372 (22.7%) 1084 (22.8%) 288 (22.0%)
Long-standing persistent and permanent 2864 (21.9%) 1997 (20.0%) 867 (28.0%) 3142 (51.9%) 2469 (52.0%) 673 (51.4%)
Calculated scores for CHADS2, CHA2DS2-VASc, and HAS-BLED are reported here.
AF, atrial fibrillation; BMI, body mass index; CrCl, creatinine clearance; COPD, chronic obstructive pulmonary disease; CRNM, clinically relevant non-major; CV, cardiovascular;
ICH, intracranial haemorrhage; NA, not available; o.d., once daily; SD, standard deviation.
aThere was no specific definition for frailty; it was left to the discretion of the physician to categorise a patient as frail.
bThe ENGAGE AF-TIMI 48 numbers refer to ischaemic/embolic stroke.

















































































































































diagnosis was symptomatic in 54% and asymptomatic in 34% of the
patients. The remaining 12% were reported as unknown by the inves-
tigator. The most common type of reported symptoms among the
symptomatic patients at baseline were palpitations (69%), followed
by dyspnoea (60%), and fatigue (58%). The median time between first
diagnosis of AF and enrolment was 4.6months (IQR: 0.4–29.9).
Frequent comorbidities included hypertension (77%), diabetes
(22%), valvular heart disease (18%), congestive heart failure (6%), and
history of myocardial infarction (4%).
Over three-quarters of patients (76%) were prescribed the full
dose of edoxaban (edoxaban 60mg). Compared with those receiving
edoxaban 60mg, patients receiving edoxaban 30mg were older and
had a lower body weight and CrCl. Furthermore, patients receiving
edoxaban 30mg had more comorbidities and a greater proportion of
these patients had a prior history of stroke and bleeding (Table 1).
The overall adherence to the summary of product characteristics
(SmPC) dosing recommendations was observed in 83% (10 859 of
13 092) patients. Non-adherence to the SmPC was observed in 11%
of patients receiving edoxaban 60mg vs. 36% of those receiving the
30mg dose. Overall, 1191 of 13 092 patients (9.1%) permanently dis-
continued from edoxaban treatment, and 11 901 of 13 092 patients
(90.9%) were still receiving edoxaban at the end of 1-year follow-up.
Patients who were prescribed the reduced dose of edoxaban
(30mg/day) despite the SmPC dosing recommendation for receiving
edoxaban 60mg had a higher mean age, mean CHA2DS2-VASc and
modified HAS-BLED scores, a lower mean CrCl, and similar mean
body weight and BMI (Table 2) compared with those receiving the
recommended full dose. Patients who were prescribed edoxaban
60mg despite the SmPC dosing recommendation for receiving the
reduced dose had a lower mean age, lower mean CHA2DS2-VASc
and modified HAS-BLED scores, a higher mean CrCl, and similar
mean body weight and BMI vs. those receiving the recommended
reduced 30mg dose (Table 2).
Mortality, stroke, and major bleeding
During the 1-year follow-up period, the overall rates of major bleed-
ing, stroke, and systemic embolism as well as all-cause mortality were
low and linearly increasing over time (Figure 1). Specifically, 442
patients died (3.5%/year), of whom 206 patients (1.6%/year) died of
CV causes (Table 3).
Major bleeding events occurred in 132 patients (1.05%/year), in
whom 51 (0.4%/year) were gastro-intestinal bleeds and 30 (0.2%/
year) were intracranial bleeds. Stroke or systemic embolism
occurred in 103 patients (0.8%/year) (Table 3). All-cause mortality,
CV mortality, any rates of stroke/SEE, and major bleeding events
were lower in ETNA-AF-Europe vs. the non-Asian ethnicity cohort
of ENGAGE AF-TIMI 48 (Table 3, Supplementary material online,
Figures S1 and S2).
Patients who were older (ranged between <65 and >_75years), frail
patients (as defined by the investigator), and patients with higher
CHA2DS2-VASc scores (>_4) were at higher risk of events (Figures 2–4).
Dosing effects
All-cause mortality, CV mortality, and rates of major bleeding were
higher in patients receiving edoxaban 30mg dose vs. those receiving
edoxaban 60mg (Table 3). Patients who were prescribed the reduced
............................................................................... ...............................................................................
....................................................................................................................................................................................................................
Table 2 Baseline characteristics of patients included in ETNA-AF-Europe receiving edoxaban 60mg and 30mg doses
in line and not in line with SmPC recommendations
Patients with the SmPC recommendation
for 60 mg (N59986)
Patients with the SmPC recommendation









Patients, N (%) 8872 (67.8%) 1114 (8.5%) 1987 (15.2%) 1119 (8.5%)
Male, n (%) 5697 (64.2%) 656 (58.9%) 713 (35.9%) 364 (32.5%)
Age (years), mean 71.1 76.4 81.3 77.3
(calc.) CHA2DS2-VASc, mean 2.8 3.4 4.0 3.6
(calc.) mod. HAS-BLED, mean 2.6 3.2 3.1 3.1
CrCl (recalculated) (mL/min), mean 86.4 69.6 41.6 51.9
Body weight (kg), mean 85.7 84.8 66.7 66.3
BMI (kg/m2), mean 29.1 29.4 25.0 24.6
Figure 1 Kaplan–Meier curve showing cumulative event rates for
major bleeding, stroke/systemic embolism, and all-cause mortality in
patients at 1-year follow-up.
















































































































































































dose of edoxaban 30mg despite the SmPC dosing recommendation
for receiving edoxaban 60mg had higher rates of all-cause death, CV
death, and major bleeding in comparison with those receiving the rec-
ommended edoxaban 60mg. However, rates of stroke/SEE and is-
chaemic stroke were not higher in those receiving the non-
recommended 30mg vs. the recommended 60mg dose (Figure 5,
Supplementary material online, Table S1). Patients who were pre-
scribed edoxaban 60mg despite the SmPC dosing recommendation
for receiving the reduced dose had lower annualized event rates of all-
cause death, CV death, major bleeding, any stroke/SEE, and ischaemic
stroke in comparison with those receiving the recommended edoxa-
ban 30mg (Figure 5, Supplementary material online, Table S1).
Using the stepwise logistic regression model, the factors related to
all-cause mortality and major bleeding were identified
(Supplementary material online, Tables S2 and S3). The main factors
included older age (defined as >_85 years and >_75 years), history of
chronic obstructive lung disease, congestive heart failure, CHA2DS2-
VASc (>_4), female sex, and edoxaban dose 30mg o.d. A higher fre-
quency of these variables was observed in patients receiving edoxa-
ban 30mg o.d., a finding that relates with an increased risk of events
in patients receiving 30mg vs. 60mg dose.
Discussion
To our knowledge, this report provides the first outcome data on
patients treated with edoxaban in routine care, enrolled into ETNA-
AF-Europe, the largest prospective, non-interventional study
investigating a single NOAC to date. The results illustrate low rates
of bleeding and ischaemic events, thereby complement data from the
ENGAGE AF-TIMI 48, the landmark randomized trial that demon-
strated superior safety and non-inferior efficacy of edoxaban vs. war-
farin. The strengths of the ETNA-AF-Europe study include a large
sample size, a prospective study design, an international setting, and
the lack of explicit exclusion criteria, validating the reliability and gen-
eralizability of data.
Various registries and retrospective analyses have looked into how
the outcomes of randomized NOAC trials may translate into routine
practice in terms of favourable safety and effectiveness of NOACs.
Low rates of stroke and major bleeding were observed in patients
receiving rivaroxaban in routine clinical practice (XANTUS regis-
try).16 In the 1-year follow-up of EURObservational Research
Programme on AF (EORP-AF) Long-Term General Registry, the cu-
mulative event-free survival from the main outcomes was the highest
amongst patients treated only with NOACs vs. other antithrombotic
agents.17 Data from retrospective analyses have also shown lower
risks of stroke/SE and lower-to-comparable bleeding events with
NOACs vs. VKAs.18,19 Findings noted in ETNA-AF-Europe now
complement the outcomes reported in other real-world registries.
Lower rates of major bleeding and stroke/SEE were observed in
ETNA-AF-Europe compared with the non-Asian ethnicity cohort of
ENGAGE AF-TIMI 48, while mortality and CV deaths were compar-
able between the two data sets. The ENGAGE AF-TIMI 48 inclusion
criteria allowed the enrolment of patients with a CHADS2 score of
at least 2, whereas the population in ETNA-AF-Europe was unse-




Table 3 Safety and efficacy outcomes in all patients included in ETNA-AF-Europe and ENGAGE AF-TIMI 48
Annualized event rates, n
(%/year) (95% CI)









adj. to 30 mg
Patients, N (%) 13092 (100%) 9991 (76.3%) 3101 (23.7%) 6056 (100%) 4747 (78.4%) 1309 (21.6%)
Primary outcomes
Major bleeding 132 (1.05) (0.88–1.25) 85 (0.88) (0.70–1.09) 47 (1.61) (1.18–2.14) 468 (2.95) 358 (2.84) 110 (3.37)
Major or CRNM bleeding 293 (2.35) (2.09–2.63) 200 (2.08) (1.81–2.39) 93 (3.22) (2.60–3.94) 1437 (10.15) 1121 (9.99) 316 (10.77)
Major GI bleeding 51 (0.40) (0.30–0.53) 25 (0.26) (0.17–0.38) 26 (0.89) (0.58–1.30) 254 (1.58) 200 (1.56) 54 (1.62)
ICHa 30 (0.24) (0.16–0.34) 23 (0.24) (0.15–0.36) 7 (0.24) (0.10–0.49) 66 (0.40) 48 (0.37) 18 (0.53)
Cardiovascular mortality
(sensitivity analysis)b
206 (1.63) (1.42–1.87) 108 (1.11) (0.91–1.35) 98 (3.34) (2.71–4.07) 456 (2.74) 287 (2.17) 169 (4.89)
All-cause mortality 442 (3.50) (3.18–3.84) 231 (2.38) (2.09–2.71) 211 (7.19) (6.25–8.23) 677 (4.06) 437 (3.31) 240 (6.95)
Secondary outcomes
Any stroke or systemic
embolism
103 (0.82) (0.67–0.99) 74 (0.77) (0.60–0.96) 29 (0.99) (0.66–1.42) 245 (1.51) 167 (1.29) 78 (2.34)
Ischaemic stroke 70 (0.56) (0.43–0.70) 50 (0.52) (0.38–0.68) 20 (0.68) (0.42–1.05) 202 (1.24) 138 (1.07) 64 (1.91)
Haemorrhagic stroke 14 (0.11) (0.06–0.19) 12 (0.12) (0.06–0.22) 2 (0.07) (0.01–0.25) 34 (0.21) 24 (0.18) 10 (0.30)
Myocardial infarction 66 (0.52) (0.41–0.67) 44 (0.45) (0.33–0.61) 22 (0.75) (0.47–1.14) 120 (0.73) 81 (0.62) 39 (1.17)
ETNA-AF-Europe and ENGAGE AF-TIMI 48 data are not intended for comparison.
CRNM, clinically relevant non-major bleeding; GI, gastrointestinal; ICH, intracranial haemorrhage.
aIntracranial haemorrhage included epidural, subdural, subarachnoid, intracerebral, or unknown haemorrhage.
bCardiovascular mortality sensitivity is a conservative exercise because also patients with an unknown or unconfirmed cause of death are calculated as CV death.




























































































































































into a lower CHA2DS2-VASc score in the ETNA-AF-Europe vs.
ENGAGE AF-TIMI 48 (3.1 vs. 4.3) which might have contributed to-
wards different event rates but may represent more generalized pre-
scribing of edoxaban since the randomized trial and marketing
authorization.
There was a good overall adherence of 83% (10 859 out of 13 092
patients) to the SmPC dosing recommendations, suggesting that the
dose reduction criteria of edoxaban are generally followed in routine
clinical care. Notably, the permanent discontinuation rate was rela-
tively low (9.1%) compared with other registries (e.g. discontinuation
rate of 20.1% at 1 year was noted in the XANTUS registry).16
A comparison of outcomes in patients receiving the two doses
generated interesting observations. More deaths and numerically
higher bleeding events were reported in patients receiving the
reduced edoxaban 30mg/day regimen. This can potentially be
explained by the fact that the criteria for dose reduction (renal im-
pairment, lower body weight, and concomitant P-gp inhibitor ther-
apy) are markers for patients at high risk of thromboembolic and
bleeding events. In line with this hypothesis, patients receiving edoxa-
ban 30mg were older (80 vs. 72 years) and had almost one point
higher CHA2DS2-VASc score (3.8 vs. 2.9) than those receiving edox-
aban 60mg. Findings observed in ETNA-AF-Europe were in line with
those reported in the non-Asian cohort of ENGAGE AF-TIMI 48,
with higher rates of bleeding, stroke, and mortality noted in the edox-
aban 30mg vs. 60mg dose group (Table 2, Figures 3–5). Of note, there
was no clear signal for a higher stroke rate.
A further exploratory analysis of patients receiving non-
recommended doses yielded noteworthy observations. Overall,
patients treated with the non-recommended doses of edoxaban
30mg and 60mg daily had an intermediate risk profile, as observed
both in the baseline characteristics and in the study outcomes. These
findings infer that physicians prescribed doses not in line with the
SmPC recommendation in patients that had ‘midway’ baseline char-
acteristics between the higher and lower dose recommendations,
and based on their clinical judgement, clinicians selected a higher or
lower dose as they deemed appropriate or that awareness of dose
reduction criteria was not scrutinized in detail or that prescribing
occurred in settings outside of the formal anticoagulation clinic set-
tings. This may explain the higher rate of annualized events of all-
cause death, CV death, and major bleeding in patients receiving the
non-recommended 30mg vs. those receiving the recommended
60mg dose. Similar patterns have been observed in patients treated
with other NOACs, with under-dosing observed to be associated
with higher risk for adverse events.20,21 Importantly, the current data
Figure 2 Kaplan–Meier curves showing cumulative event rates for stroke/systemic embolism in patients at 1-year follow-up classified by: (A) edoxa-
ban dose, (B) age groups, (C) frailty status, and (D) CHA2DS2-VASc groups.




















































































































































set is not powered to assess small differences in stroke rates, but
there was no signal for a higher stroke rate in patients receiving the
non-recommended low dose of edoxaban. However, there are too
few events in patients taking the non-recommended doses to deter-
mine a clinically relevant, substantial difference compared with those
taking the recommended doses. A longer follow-up of ETNA-AF-
Europe may provide more information on the effects of non-
approved dosing.13
Advancing age and accumulation of comorbidities, including vascu-
lar disease, heart failure, diabetes, chronic kidney disease, as well as
frailty are believed to increase thromboembolic and bleeding risks in
patients with AF.22 In line with existing data for elderly patients,22 the
ETNA-AF-Europe registry reported higher rates of clinical outcomes
in elderly patients. Noticeably, the real-world penetration of anticoa-
gulation in elderly and frail patients remains low. It is despite this
population being at a higher risk for ischaemic events by virtue of
their age and burden of associated comorbidities,23 and may be
driven by a fear of bleeding associated with the use of oral anticoagu-
lation.24 Furthermore, VKAs remain commonly used.25 Compared
with VKAs, NOACs have been associated with lower risks of
thromboembolic events, major bleeding, and all-cause death in octo-
genarian and frail patients.6,8,26,27 The ETNA-AF-Europe dataset
demonstrates a low and constant rate of ICH in elderly and younger
patients with AF, replicating findings observed in patients receiving
other anticoagulants16 and the constant ICH rate across edoxaban
plasma concentrations in ENGAGE AF-TIMI 48 in non-Asian
patients.28 Increased rates of other bad outcomes were observed in
frail vs. non-frail patients, as simply reported by investigators, included
in the ETNA-AF-Europe registry. The data accumulated so far includ-
ing ETNA-AF-Europe reinforce the ability of NOACs, and particular-
ly edoxaban, to improve outcomes and quality of life in elderly and
frail patients.
A trend towards a greater rate of major bleeding events occurred
within the first month of initiating the study in high-risk patients,
including those receiving edoxaban 30mg, the elderly and frail popu-
lation, and those with CHA2DS2-VASc score >_4; while stroke/SEE
and all-cause mortality were more evenly distributed over the 1 year
of follow-up. This is most likely related to unmasking of bleeding
Figure 3 Kaplan–Meier curves showing cumulative event rates for major bleeding events in patients at 1-year follow-up classified by: (A) edoxaban
dose, (B) age groups, (C) frailty status, and (D) CHA2DS2-VASc groups. Major bleeding was defined as a clinically overt bleeding event (i.e. bleeding
that is visualized by examination or radiologic imaging) that meets at least one of the following: (A) Fatal bleeding. (B) Symptomatic bleeding in a critical
area or organ such as, retroperitoneal, intracranial, intraocular, intraspinal, intra-articular, pericardial, and intramuscular with compartment syndrome.
(C) A clinically overt bleeding event that causes a fall in haemoglobin level of 2.0 g/dL (>1.24 mMol/L) or more; or a fall of haematocrit of 6.0% or
more, adjusted for transfusion.


























































































Figure 4 Kaplan–Meier curves showing cumulative event rates for all-cause mortality in patients at 1-year follow-up classified by: (A) edoxaban
dose, (B) age groups, (C) frailty status, and (D) CHA2DS2-VASc groups.
Figure 5 Major bleeding and stroke/SEE in ETNA-AF-Europe patients dosed in line and not in line with SmPC recommendations. SE, systemic em-
bolism; SmPC, summary of product characteristics.







































































































































































































































































predisposition in frail patients that had just initiated the treatment regi-
men. Similar observations were made with warfarin, showing the high-
est risk of haemorrhage at the initiation of anticoagulant therapy.29
Limitations
We acknowledge limitations with this routine clinical care study.
ENGAGE AF-TIMI 48, a controlled phase III trial, was better
equipped to ensure medication adherence, while routine care
(ETNA-AF-Europe) usually relies on patients to take medications dis-
pensed without further checks by a pharmacy. Another difference is
the reduced ability to chase missing information in routine care vs. a
randomized trial. Although follow-up rates in ETNA-AF-Europe
were good; however, the numbers were lower than those available
for ENGAGE AF-TIMI 48 at 1 year. In ETNA-AF-Europe, direct com-
parison of casual treatment effects was not possible as there was no
randomized selection of therapy and only patients treated with edox-
aban were here eligible. This data set captures events in patients
treated with edoxaban early after its approval, potentially selecting
patients and health professionals who are ‘early adopters’. The obser-
vational nature of therapy with an already approved anticoagulant
may decrease the alertness to report non-serious events leading to
incomplete capturing of events. Owing to the observational design of
the study, systematic information on laboratory and other investiga-
tions is not available as would be in a trial setting. Furthermore, the
open-label nature of the study may have introduced bias due to
knowledge about treatment.
Conclusions
Edoxaban therapy in routine practice in ETNA-AF-Europe has
reported low ischaemic and haemorrhagic events, including ICH in
the first year after initiation in an unselected cohort of patients with
AF, despite half of all patients being aged >_75 years. The adherence
to recommended trial dosing was high (83%). Low event rates were
found across ages and comorbidities, including elderly and very elder-
ly patients, frail patients and in patients with increased stroke risk.
These data illustrate the effectiveness and safety of edoxaban in rou-
tine care in Europe captured in ETNA-AF-Europe, the first NOAC
post-authorization safety study approved by the European Medicines
Agency and mandated to have minimal disruption to routine care.
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The data underlying this article are available in the article and in its
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